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Abstract
Background: Effectiveness of early intensive aphasia rehabilitation after stroke is unknown. The Very Early
Rehabilitation for SpEech trial (VERSE) aimed to determine whether intensive aphasia therapy, beginning within
14 days after stroke, improved communication recovery compared to usual care.
Methods: Prospective, randomized, single-blinded trial conducted at 17 acute-care hospitals across Australia/
New Zealand from 2014 to 2018. Participants with aphasia following acute stroke were randomized to receive usual
care (direct usual care aphasia therapy), or one of two higher intensity regimens (20 sessions of either non-prescribed
(usual care-plus or prescribed (VERSE) direct aphasia therapy). The primary outcome was improvement of communication on the Western Aphasia Battery-Revised Aphasia Quotient (AQ) at 12 weeks after stroke. Our pre-planned
intention to treat analysis combined high intensity groups for the primary outcome.
Findings: Among 13,654 acute stroke patients screened, 25% (3477) had aphasia, of whom 25% (866) were eligible and
246 randomized to usual care (n ¼ 81; 33%), usual care-plus (n ¼ 82; 33%) or VERSE (n ¼ 83; 34%). At 12 weeks after
stroke, the primary outcome was assessed in 217 participants (88%); 14 had died, 9 had withdrawn, and 6 were too
unwell for assessment. Communication recovery was 50.3% (95% CI 45.7–54.8) in the high intensity group (n ¼ 147) and
52.1% (95% CI 46.1–58.1) in the usual care group (n ¼ 70; difference 1.8, 95% CI 8.7–5.0). There was no difference
between groups in non-fatal or fatal adverse events (p ¼ 0.72).
Interpretation: Early, intensive aphasia therapy did not improve communication recovery within 12 weeks post stroke
compared to usual care.
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Introduction
Evidence before this study
The 2016 Cochrane review1 indicates that aphasia therapy is eﬀective for chronic language/communication
recovery. There is no Level 1 evidence for the eﬀectiveness of aphasia treatments started within the ﬁrst two
weeks post stroke when the proposed ‘window of
opportunity’2 for enhanced neuronal recovery is at its
peak. The few studies which commenced treatment
within the ﬁrst 15 days post stroke have mixed ﬁndings;3–5 the most recent study (Rotterdam Aphasia
Therapy Study-3 (RATS-3))3 suggested that early intervention is no better than starting therapy after the ﬁrst
month post stroke.

Added value of this study
VERSE6 is the ﬁrst international aphasia trial, which
recruited from 17 acute hospitals. VERSE participants
were followed up at 45 subacute and community
healthcare centers to six months post stroke. VERSE
will contribute to Level 1 evidence about the eﬀectiveness of intensive early aphasia therapy compared to
usual care in a broad population of acute aphasic
stroke patients. Very early intensive, aphasia therapy
during the hypothesized optimal recovery window2
had no additional beneﬁt to language impairment, discourse/connected speech, quality of life, or depression
at 12 or 26 weeks post stroke to usual care. Critically,
there was a large increase in amount of aphasia therapy
in this trial (9.5 h up from a total of 14 min) compared
to our earlier pilot study5, which looked promising.
Our ﬁndings are in line with those of the A Very
Early Rehabilitation Trial (AVERT)7 whereby an
increase in the intensity of ‘usual care’ services from
pilot studies to the main study was reported and the
Phase III trial was subsequently negative. Taken
together with the AVERT7 results, VERSE provides a
useful guide for the design and analysis of future stroke
rehabilitation RCTs in early stroke recovery.

Background
Aphasia (language impairment aﬀecting spoken language, comprehension, reading and writing) is not
rare, aﬀecting approximately one in three8 of the 16.9
million people worldwide who experience stroke each
year.9 People with aphasia have greater mortality and
morbidity, lower levels of social participation and
return-to-work rates, and an almost three-fold greater
risk of experiencing depression than stroke survivors
without aphasia.10 The recent global estimates of
post-stroke aphasia burden in relation to annual disease costs are AUD$49.3 billion11 ($34.4b USD).
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Restorative and compensatory rehabilitation delivered by speech pathologists is the mainstay of treatment
for aphasia. There are no animal equivalent basic science models to drive aphasia recovery research. The
theoretical constructs that underpin aphasia research
derive from an integration of cognitive and motor theoretical domains, and extrapolation is required to
explain language recovery. Evidence from human
motor and animal stroke recovery models suggests the
ﬁrst 90 days post stroke is the ‘window of opportunity’2
where the greatest potential to harness spontaneous
recovery exists.12 This theory suggests that high frequency repetition should strengthen neural networks
and minimize independent neuronal activation,
potentially reducing maladaptive behaviors.2,12
Neurorecovery therapeutic principles guide rehabilitation research and aim to strengthen interaction within
and between neural networks and to promote improved
accuracy and eﬃciency of function.2,12 Eﬃcacy of
aphasia therapy for functional communication was
established in the Cochrane review (27 randomized
trials including 1620 patients)1 and supported by a
recent European trial13 which showed the beneﬁt of
intensive aphasia therapy in chronic recovery. The
trial provided 10 h of direct therapy per week for
three weeks for a total of 31 (median) h with an additional 15 h (total) of home practice.
Currently, there is no Level I evidence that directly
addresses the timing, intensity, and type of aphasia
therapy, commencing within the ﬁrst two weeks post
stroke.1 Mixed results are noted from various studies3–5
comparing treatment intensity when intervention was
commenced within two weeks post stroke. Laska
et al.4 (N ¼ 123) reported no beneﬁt in speech production and comprehension (Norsk Grunntest for Afasi14)
or in functional communication (Amsterdam–
Nijmegen Everyday Language Test15) after 15 h of a
comprehension-based intervention across three weeks,
when compared to no therapy. Our Phase I pilot study5
(N ¼ 59) indicated a statistical and clinical beneﬁt from
daily intensive therapy targeted at spoken language.
Over a mean of 19 days, 7.5 h of therapy (or 2.7 h per
week) was compared to standard care (on average <1 h
in total). Language and communication beneﬁts were
observed at therapy completion and six months post
stroke on the Western Aphasia Battery-Revised16 and
the Functional Communication Proﬁle.17 The more
recent RATS-3 trial3 (N ¼ 153) demonstrated no beneﬁt
of early therapy consisting of 24.5 h over four weeks
(6.1 h per week) when compared to no therapy in the
ﬁrst month, measured at 4, 12, and 26 weeks post
stroke. However, only 29% of the intervention group
complied with the prescribed treatment dose of 28 h of
direct aphasia therapy. The ‘per-protocol’ analysis of
the RATS-3 trial3 identiﬁed beneﬁt of early treatment
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compared to no treatment at four weeks post stroke, on
measures of spoken language. Our Phase II pilot trial18
(N ¼ 20) that was designed to investigate the eﬀect of
treatment type received in early aphasia recovery
(group therapy vs. individual therapy), for 20 h provided over four weeks (5 h per week), which is at the
lower intensity range found to be eﬀective.19 The trial
found no between-group diﬀerence.
While there is no Level 1 evidence for the eﬀectiveness of very early aphasia therapy, similar research had
been completed in the area of physical rehabilitation
through the AVERT trial.7
The uncertainty around the timing, intensity, and
type of aphasia therapy in the very early stroke recovery window (commencing therapy before day 15 post
stroke) prompted the VERSE trial.6,20 Our primary
hypothesis was that compared to usual care alone
(UC), higher dose early aphasia therapy would result
in improved language and communication at 12 weeks
post stroke, measured by the Western Aphasia BatteryRevised16 (primary outcome) and discourse analysis21
(secondary outcome). To explore the question of therapy type, the higher dose therapy could be delivered in
one of two ways (UC-Plus and VERSE therapy—outlined below). We further hypothesized that
higher dose training would result in better quality of
life, and be cost eﬀective. This article reports primary
and key secondary outcomes for the trial.

Methods
Study design
A phase three, multicenter, randomized controlled trial,
with allocation 1:2 (UC: UC-Plus and VERSE) and
blinded outcomes assessed at 12 (primary outcome)
and 26 weeks post stroke. The trial protocol6 and statistical analysis plan (SAP)20 were accepted for publication before unblinding (see Supplement and
publications for full trial methodology description).
The trial was approved by hospital ethics committees
and all participants gave written informed consent
using aphasia friendly consent processes.22

3
any type, within 14 days of stroke onset. They required
a score of less than 93.7 on the Aphasia Quotient of the
Revised Western Aphasia Battery (WAB-R AQ)16 indicating mild to severe aphasia. They were medically
stable, could maintain a wakeful alert state for at
least 30 min, and had normal or corrected hearing
and vision. Exclusion criteria were pre-existing aphasia
and dementia, a concurrent progressive neurological
disorder, any head injury, neurosurgery, clinical depression at admission, inability to participate in Englishbased therapy, or participation in other concurrent
intervention trials.
Qualiﬁed speech pathologists trained to screen and
consent participants, diagnosed aphasia using the
Frenchay Aphasia Screening Test,23 and enrolled eligible participants.

Randomization and masking
Baseline assessments were completed by trained staﬀ
before randomizing participants using a computer-generated, block randomization sequence (permutated
block of six, with 1:1:1 randomization to three groups
(UC, UC-Plus, VERSE) to achieve an overall ratio of
1:2 (UC; high intensity therapy, combined UC-Plus and
VERSE)19 via Research Electronic Data Capture
(REDCapTM).24 Randomization was performed by
the baseline assessor who was not otherwise involved
in the trial and participants were stratiﬁed by aphasia
severity determined by the WAB-R (AQ) score.
Participants, family members, ward staﬀ, and outcome
assessors were not informed of group allocation and all
participants and trial staﬀ were asked not to discuss
treatment received. Only UC staﬀ wrote in medical
notes per healthcare standards and all research documentation was stored separately in a secured location
to avoid unblinding. Blinded outcome assessors were
not involved in participants’ stroke care and were not
permitted to ask participants about treatment received
during follow-up assessments. Only treating therapists
(acute and subacute) were unblinded to treatment
allocation.

Procedures—Treatment intensity and type
Participants
Participants required the capacity to consent to be eligible and were recruited from 17 acute-care hospitals in
Australia and New Zealand and then followed up at 45
subacute and community healthcare centers.

Eligibility criteria
Participants were aged over 18 years and admitted to
hospital with an acute stroke, resultant acute aphasia of

All speech pathology services received by participants
up to 26 weeks post stroke were recorded for all
groups.6 Our focus was the recording of direct aphasia
therapy which was deﬁned as ‘treatment designed to
restore language and communication function’ and
could consist of individual or group social and or
impairment-based treatment, social or communication
device training. Education, counseling, goal-setting,
treatment programming, documentation, and consultation were excluded from these analyses.20
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Usual care

Outcomes

Participants randomized to the UC arm constituted the
trial control group. UC aphasia therapy was standard
care at each site and was not controlled for amount,
frequency of sessions, therapy type, or therapist. For
data reporting purposes, we asked UC therapists to
record all aspects of management and to video record
aphasia therapy sessions, although videorecording was
not mandatory.

The trial SAP20 outlines the primary and secondary
outcomes in detail. Our primary outcome was improvement in communication at 12 weeks after stroke, measured by the WAB-R AQ which is a sensitive, valid and
reliable measure of aphasia performance with a standard error of measurement of 3 points.27 Improvement
was assessed using the percent of maximal potential
recovery achieved (%MPR).28 The %MPR represents
a percentage score of the maximum potential change
(i.e. the endpoint score minus the baseline score) allowing for direct meaningful comparison of amount of possible improvement on the WAB-R AQ for people with
varied aphasia severity. Using the %MPR also
accounts for the ceiling eﬀects of the standardized
test. All raw scores are presented in Supplemental
Table S3. Based on benchmarking of aphasia intervention studies, a 5-point change on the WAB-R AQ represents a conservative, clinically meaningful eﬀect.29
Secondary outcomes were: treatment eﬀectiveness
(both %MPR and discourse measures20) at 26 weeks,
word naming (Boston Naming Test30), quality of life
(Stroke and Aphasia Quality of Life scale-3931), depression (Aphasia Depression Rating Scale32) at 12 and 26
weeks. The Aphasia Depression Rating Scale was completed by the participant with communication support
from the blinded assessor. Safety (adverse and serious
adverse events) was assessed at 12 and 26 weeks post
stroke. Adverse event reporting followed a protocol,20
an independent medical oﬃcer adjudicated events, and
reported to the Data Safety and Monitoring Board.

High intensity therapy regimens
Participants randomized to either of the high intensity
groups (UC-Plus or VERSE) received usual care therapy and had additional aphasia therapy provided by
specially trained therapists. UC-Plus therapy involved
any combination of therapy at the discretion of the
therapist. Participants were prescribed 20 sessions of
45–60 min (15–20 h; or 4–5 h per week) of aphasia therapy, commencing before day 15 and completed within
four weeks.16,20 The intensity level for these groups was
chosen in-line with available evidence (5 h per week19)
and demonstrated tolerability.5,18
VERSE treatment was an impairment-based therapy
program (see Supplement; Intervention Protocol),
developed by an aphasia Expert Advisory Committee.
The VERSE intervention prioritized error-free, verbal
communication, encouraging conversation while working between 50% and 80% accuracy at each goal level
to maintain a therapy challenge point. In both higher
intensity groups, the amount of therapy and the timing
of commencement of intervention were standardised.6

Statistical analysis
Training, therapy, and assessment fidelity
All treating speech pathologists underwent protocol
training and received procedural training manuals relevant to the arm of therapy they provided. Training
details and treatment manuals are provided in
Appendix 1. Clinical support was given by central
research staﬀ for UC-Plus therapists, and a VERSE
Therapy Coordinator provided feedback and support
for VERSE therapists. UC-Plus and VERSE therapists
were allocated to a therapy group from a therapist
recruitment pool, depending on trial needs. Therapists
providing UC-Plus and VERSE intervention groups
were mandated to video record a therapy session each
week and submit this to an independent therapy integrity monitor for review and veriﬁcation (see
Supplement—Main and Intervention Protocols). All
data discrepancies were queried by the Monitor with
clinical staﬀ and all queries resolved prior to database
lock in compliance with all elements of the TIDiER25
and SPIRIT26 statements.
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The trial was powered (80% power, 5% signiﬁcance
level) to detect a between-group diﬀerence (UC vs.
high intensity groups) of 20% on %MPR (primary)
at 12 weeks. Adjusting for expected 20% (high level)
lost to follow-up, a total of 246 participants was
planned.20 This was also suﬃcient to detect a 4.4%
between-group diﬀerence (UC-Plus compared to
VERSE) on the %MPR. Using an intention-to-treat
basis, our primary analysis compared higher intensity
therapy (UC-Plus and VERSE groups combined) to
UC on the %MPR on the WAB-R AQ at 12 weeks
post stroke using a linear mixed model which controlled
for baseline WAB-R AQ and baseline National
Institute of Health Stroke Scale (NIHSS)33 as ﬁxed
eﬀects and hospital site as a random eﬀect.20
Unadjusted results for both primary and secondary
analyses are also reported. Safety analyses are reported
in Table 1.
The primary and secondary outcome analyses are
reported without imputation of missing data,20
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Table 1. Adverse events and serious adverse events
Unadjusted analysis
UC
(n ¼ 81)
No. of adverse events

33

No. of deaths (%)

4 (5)

Depression
Neurological Complications

19 (23.5)
2 (2.5)

High intensity
(n ¼ 164)

p value

Odds ratio (95% CI)

p ¼ 0.08a

1.62 (0.92–2.89)

10 (6)

p ¼ 1b

1.24 (0.34–5.60)

35 (21)

p ¼ 0.69a

0.88 (0.45–1.76)

9 (5.5)

p ¼ 0.35b

2.27 (0.45–22.10)

p ¼ 0.11b

–

121 (73.3)

–

–

87

No. of serious adverse events (%)
0

68 (84)

1

12 (14.8)

29 (17.6)

–

1.36 (0.62–3.12)

2

1 (1.2)

9 (5.5)

–

5.03 (0.67–224.67)

>2

0 (0)

6 (3.6)

–

1 [infinite] (064–1)

UC: usual care.
Data are n (%).
a
Chi-square test.
b
Fisher’s exact test.

supplemented by analyses with imputed data sets (see
Supplement p. 7—Imputation Plot).20 An additional
eﬃcacy subgroup analysis explored age, sex, baseline
aphasia severity (AQ), and disability (mRS34).
Subgroup analysis of treatment type (UC-Plus compared to VERSE subgroup comparisons) used a
linear mixed model (see Supplemental Table S2). No
adjustments were made to p values for multiple comparisons in subgroup analyses or the analyses of secondary outcomes. All analyses were completed using
R35 and statistical analyses were performed by the
trial statistician and veriﬁed by a statistician blinded
to group allocation. The trial was registered with the
Australian New Zealand Clinical Trials Registry
(ACTRN12613000776707); and Universal Trial
Number (U1111-1145-4130).

Data availability
VERSE individual deidentiﬁed participant trial data
(including data dictionary) will be available through
the CATS36 international aphasia data repository.

Results
Between 4 June 2014 and 10 February 2018, 13,654
patients with acute stroke were screened; 3477 (25%)
had aphasia, 866 (25%) of whom were trial eligible, and
246 (28%) participants were enrolled (Figure 1). Last
patient, last visit occurred on 31 July 2018. One

randomized participant withdrew consent; their data
were withdrawn from analysis (N ¼ 245). At the primary endpoint (week 12), 14 (6%) participants had
died, 9 (4%) had withdrawn, and 6 (2.5%) were too
unwell for assessment, leaving 217 (88%; within the
20% lost to follow-up allowance20) participants in the
primary analysis.
Baseline demographic, stroke, and communication
characteristics were balanced across all groups, except
for greater concomitant dysarthria (frequency and
severity) in the UC group (Table 2; see Supplemental
Table S1 for demographics all groups). A third of participants were over 80 years and 71% had moderate to
severe aphasia (WAB-R AQ  62.5). Participants were
randomized at median 9 (IQR 5) days after stroke onset
and 224 (91%) participants received therapy within the
ﬁrst two weeks of stroke (Table 3). As intended, the
high intensity groups received treatment two days earlier than those receiving UC (p ¼ 0.008).
The high intensity groups completed 20 sessions
across 32 days (median) and received a total mean
time of 22.7 h (SD 8.4) h of aphasia therapy (average
of 5 h per week). This compared to 9.5 (SD 7.6) mean
hours over 28 (17) days (median, IQR; average of 2.3 h
per week) in the UC group (Table 3). Four (5%) participants in the UC group received no aphasia therapy
during the intervention period. Usual care therapists
submitted three of the total 434 (<1%) video recorded
aphasia therapy sessions. Between the end of the prescribed intervention and the primary endpoint at week

International Journal of Stroke, 0(0)
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Figure 1. CONSORT study flow diagram.

12, all participants received usual care speech-language
services: participants in the high intensity group
received a mean of 3.3 (SD 6.0) additional hours of
therapy; UC participants received a mean of 2.9 (SD
5.4) additional hours. Limited additional therapy was
provided after week 12 (Table 3). The intensive intervention was delivered per protocol to 82% (n ¼ 164) of
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those randomized to UC-Plus and VERSE groups
(Supplemental Table S2). Among the 29 participants
who did not receive the full intervention, 22 were due
to death/illness/fatigue or refusal, 6 to intervention
protocol non-adherence, and 1 was due to insuﬃcient
staﬃng. Table 4 outlines the therapy components of
UC, UC-Plus, and VERSE.
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Table 2. Baseline characteristics of the intention-to-treat population
Usual care (n ¼ 81)

High intensity (n ¼ 164)

Recruitment region
Australia (n, %)

75 (93%)

155 (94%)

6 (7%)

10 (6%)

76 (17)

75 (18)

<65

20 (25%)

43 (26%)

65–80

37 (46%)

67 (41%)

>80

24 (30%)

54 (33%)

Male (n, %)

38 (47%)

84 (51%)

Female (n, %)

43 (53%)

80 (49%)

Home alone (n, %)

25 (31%)

44 (27%)

Home with other

53 (65%)

115 (70%)

New Zealand
Patient details
Age (mean, SD)

Sex

Pre-morbid history (living arrangements prior to stroke)

Supported accommodation

0 (0%)

1 (<1%)

Unknown

3 (4%)

4 (3%)

Hypertension (n, %)

42 (52%)

83 (51%)

Ischemic heart disease

18 (22%)

53 (32%)

Atrial fibrillation

25 (31%)

44 (27%)

Hypercholesterolemia

10 (12%)

16 (10%)

9 (11%)

25 (15%)

10 (12%)

18 (11%)

Stroke risk factors

Diabetes
Current smoker
Baseline NIHSS

8 (7)

9 (6)

Oxfordshire Stroke Classification
TACS (n, %)

17 (21%)

35 (21%)

PACS

55 (68%)

110 (67%)

POCS

3 (4%)

6 (4%)

LACS

0 (0%)

0 (0%)

Hemorrhage

6 (7%)

13 (8%)
(continued)
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Table 2. Continued
Usual care (n ¼ 81)

High intensity (n ¼ 164)

Time to Randomization (days)

9 (4)

10 (5)

Frenchay Aphasia Screening Test

5 (8)

5 (8)

42.4 (28.9)

40.5 (27.8)

Mild (93.6–62.6)

25 (31%)

47 (29%)

Moderate (62.5–31.3)

24 (29%)

49 (30%)

Severe (0–31.2)

32 (40%)

68 (41%)

22 (27%)

41 (25%)

159 (171)

151 (204)

74 (97)

70 (110)

15.1 (25.7)

14.0 (25.8)

15.9 (17.4)

13.2 (16.3)

50 (62%)

80 (49%)

38 (47%)

79 (48%)

Western Aphasia Battery-Revised Aphasia Quotient (mean, SD)

Discourse measures (>200 words; N ¼ 229)
Number of words
Number correct information units
% correct information units
Boston Naming Test (N ¼ 242; mean, SD)
AusTOMS—dysarthria
No impairment (n, %)
Apraxia of speech
No impairment (n, %)
Clock drawing/cognition test, median (IQR; N ¼ 239)
Dysphagia present (n, %)

1 (3.5)
43 (53%)

1 (3)
89 (54%)

NIHSS: National Institutes of Health Stroke Scale; mRS: modified Rankin Scale; TACS: total anterior circulation stroke; PACS: partial anterior circulation
stroke; POCS: posterior circulation stroke; LACS: lacunar stroke; AusTOMS: Australian Therapy Outcome Measures.
Data are mean (SD), n (%), or median (IQR).

At 12 weeks post stroke, the unadjusted
mean %MPR of those in the high intensity group
(UC-Plus and VERSE) was 50.5% (SD 32.4) compared
to 52.9% (SD 29.5) in the UC group (Table 5).
Our primary analysis (adjusted) showed recovery at
52.1% for the UC group (95% CI 46.1–58.1) and
50.3% (95% CI 45.7–54.8) for the high intensity
group, after controlling for baseline AQ, NIHSS, and
hospital site. The between-group diﬀerence of 1.8
(favoring control; (95% CI 8.7–5.0) was not signiﬁcant (p ¼ 0.59; Figure 2; Supplemental Table S3 for all
group comparisons). Multiple imputations for missing
data, assuming the data were missing at random,
showed similar results. Deviations from this assumption were assessed through a sensitivity analysis
(Supplemental Figure S1).
The results were similar across all secondary outcomes with no statistically signiﬁcant diﬀerences
noted (Table 5). The pre-speciﬁed exploratory analysis
of subgroups20 found no statistically signiﬁcant
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diﬀerences for any variables (Supplemental Figure
S3). The subgroup comparisons for %MPR at 12
weeks was 52.2% for the VERSE group (95% CI
46.3–58.2) and 48.4% for the UC-Plus group (95%
CI 42.5–54.3; Supplemental Table S3).
By the 26-week follow-up, 202 participants (82%),
consisting of 139 (85%) participants from the high
intensity group (70 (85%) UC-Plus and 69 (83%)
from VERSE) and 63 (78%) participants from the
UC group, were assessed. At this time point, the overall
group mean %MPR was 56.9% (SD 32.2).
The high intensity group %MPR was 54.7% (SD
34.6) and the UC %MPR was 61.7% (SD 25.8) indicating greater recovery for usual care participants, though
not statistically signiﬁcant (p ¼ 0.12). There were no
signiﬁcant diﬀerences in non-fatal or fatal adverse
events between groups (Table 1). New cases of depression were diagnosed in 35 (21%) participants in the
high intensity group compared with 19 (23.5%) in
UC (p ¼ 0.67).

Godecke et al.

9

Table 3. Hospital stay and intervention characteristics
UC
(n ¼ 81)

High intensity
(n ¼ 164)

p value

Median shift, mean difference
or odds ratio (95% CI)

20.5 (40)

p ¼ 0.2b

Median shift ¼ 3.0 (1.0–8.0)

Length of inpatient stay (days)

15 (27)

Time to first therapy (days)

10 (8)

8 (6)

p ¼ 0.008b

Median shift ¼ 2.0 (1.0–3.0)

Received rtPA treatment

17 (21)

26 (16)

p ¼ 0.32a

OR 1.4 (95% CI: (0.7–2.8))

Received therapy as inpatient

77 (95)

164 (100)

p ¼ 0.011d

OR ¼ 1 [infinite] (1.4–1)

Received therapy within 15 days

64 (79)

160 (98)

p < 0.001a

OR ¼ 10.5 (3.3–44.6)

135 (82)

p ¼ 0.94a

OR ¼ 0.97 (0.44–2.05)

Trial protocol compliant

-

Number of intervention
days (median (IQR))

28 (17)

32 (7)

p ¼ 0.019e

Median shift ¼ 3.0 (0.0001–5)

Number of therapy sessions
(intervention period)

12 (11)

30 (14.2)

p < 0.001b

Median shift ¼ 16.0 (14.0–19.0)

Sessions per week

3.1 (2.7)

6.4 (2.9)

p < 0.001b

Median shift ¼ 2.9 (2.4–3.4)

Length of session (minutes)

37.2 (11.7)

45.3 (8.5)

p < 0.001c

Mean difference ¼ 8.1 (5.1–11.0)

Intervention—total therapy

9.5 (7.6)

22.7 (8.4)

p < 0.001c

Mean difference ¼ 13.2 (11.0–15.3)

Week 12 total therapy amount (hours)

12.4 (10.6)

26.0 (11.1)

p < 0.001c

Mean difference ¼ 13.6 (10.7–16.5)

Week 26 total therapy amount (hours)

15.4 (13.4)

28.7 (14.7)

p < 0.001c

Mean difference ¼ 13.3 (9.6–17.0)

r

tPA: recombinant tissue plasminogen activator; UC: usual care.
Data are n (%), median (IQR), or mean (SD).
a
Chi-square test.
b
Mann–Whitney test.
c
t test.
d
Fisher’s exact test.
e
Wilcoxon rank-sum test.

Discussion
We conducted the largest, multicenter aphasia clinical
trial in stroke to date, assessing the eﬀectiveness of
aphasia therapy in very early post-stroke recovery.
Designed to determine if ‘more intensive aphasia therapy is better’ in the acute post-stroke phase, our early
intensive therapy regimen commenced on average two
days earlier and was delivered more frequently and in a
greater amount than in UC. We found that 22 h (or an
average 5 h per week) of aphasia therapy (regardless of
type) delivered over 32 days, showed no beneﬁt over
9.5 h delivered over 28 days (2.3 h per week) for the
primary outcome WAB-R AQ at 12 weeks post
stroke. That is, more therapy started on or before day
eight post stroke, did not signiﬁcantly enhance language or communication recovery, or global outcomes
such as quality of life or depression at 12 or 26 weeks.
Provision of more intensive therapy did not result in
greater adverse outcomes and was safe and feasible to

deliver. The majority of participants in the VERSE
trial, regardless of group allocation, achieved signiﬁcant, clinically meaningful gains in language recovery.
We believe the trial sample was representative of a typical population with post-stroke aphasia evidenced by
the severity of stroke and aphasia recruited to this
trial.8 Our 7% recruitment rate is consistent with
recruitment for acute stroke trials.7
Our current ﬁndings were unexpected, based on our
pilot studies5,18 which showed signiﬁcant beneﬁt of
early, intensive aphasia treatment. In addition, we
found a considerable increase in the amount of aphasia
therapy provided as usual care, but not in the type of
therapy provided,37 compared with the results of our
pilot trial.5 Our Phase I trial5 was conducted over 10
years ago, and at this time, among the 15% of participants who received aphasia therapy, only 14 min was
provided in a single session over three weeks. The shift
in usual care service delivery in this trial was evidenced
by 81% of UC participants receiving: (i) early aphasia

International Journal of Stroke, 0(0)

10

International Journal of Stroke 0(0)

Table 4. Treatment components (type) of usual care, usual care-Plus, and VERSE intervention
Treatment characteristic

Usual care

Usual care-Plus

VERSE

Treatment individually tailored

3

3

3

Treatment included reading and writing

3

3



Task appropriate for goal/participant

3

3

3

45–60 min direct intervention recorded

3

3

3

Cueing strictly followed hierarchy





3

Successive cues following each error





3

High verbal output by patient

/3

/3

3

Reduced verbal output by clinician

/3

/3

3

Therapy embedded in conversation

/3

/3

3

Verbal output within challenge point

/3

/3

3

Salient everyday communication exchanges

/3

/3

3

VERSE: Very Early Rehabilitation for SpEech study.

therapy within the ﬁrst 15 days post stroke; (ii) more
frequent sessions (3 per week), and (iii) 9.5 h of aphasia
therapy over 28 days. These changes may reﬂect a
greater focus on national clinical guidelines38 with recommendations to increase the amount of aphasia therapy based on expert consensus inﬂuenced by early, yet
underpowered trials. They may also reﬂect the fact that
the sites in this trial were self-selected, hence it may be
that these sites have an increased number of therapists
compared to other sites who did not participate in the
trial. The increase in UC aphasia services may also be
the result of an increased will to ‘do more’ as part of the
trial, a phenomenon known as the ‘Hawthorn Eﬀect’,
secondary to recording and monitoring of these services. For the Usual Care therapy sessions, fewer than
1% of sessions were video recorded despite the larger
than expected number of hours of aphasia therapy that
were provided to this group in the trial. We believe the
low number of recorded sessions in this group reﬂects
standard videorecording practice at these sites.
Results presented here are suggestive of the economic ‘law of diminishing returns’ applied within a
medical service delivery model which speciﬁes that
‘‘beyond a certain point, additional inputs produce
smaller and smaller outputs’’39 (p. 371). Our suﬃciently
powered trial shows diminishing marginal returns from
the additional aphasia therapy provided in early stroke
recovery. The small diﬀerence observed in %MPR
(1.8%) between the UC and high intensity cohorts at
12 weeks post stroke, means a 1.8 point diﬀerence
for a profoundly impaired participant with a baseline
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WAB-R AQ score of 0 (no verbal output). For a participant with a baseline AQ of 40 (average for our trial
and indicative of a participant speaking in two-word
phrases with frequent errors and word-ﬁnding diﬃculties), the between group diﬀerence equates to 1.14
points at 12 weeks. These small group diﬀerences
were not considered clinically relevant (deﬁned as 5
points29 on the WAB-R AQ).
The within group diﬀerences (over 25 points) were
between 50% and 52% of MPR. From a clinical perspective, it was reassuring to show the majority of
VERSE participants achieved a large and clinically
meaningful gain in language recovery, regardless of
group allocation, and this was consistent with our earlier trials.5,18 Clinically, the average participant progressed from speaking in two-word phrases with
multiple word, sound and grammatical errors and
requiring assistance with all communication interactions, to speaking in coherent and appropriate sentences. Prior research to predict maximal potential
aphasia recovery in acute stroke has been limited to
a sample of 21 patients whereby the predicted
improvement within the ﬁrst 12 weeks was estimated
at 70%.28 Our ﬁndings suggest that average predicted
recovery from aphasia at 12 weeks may be somewhat lower than that. However, our ﬁndings reﬂect
considerably more change than expected in people
with chronic aphasia (>6 months post stroke)
where interventions are considered to be potent if
they deliver change of 5-points28 or more on the
WAB-R AQ.

367 (297)
253 (242)
58 (26.4)
3.6 (0.76)
5.6 (3.77)

No. of wordsc

No. of correct information units

% Correct information units

Stroke and Aphasia Quality of Life Scale-39

Aphasia Depression Rating Scale

61.7 (25.5)

% Maximal potential recovery

42 (60)
379 (337)
266 (276)
62.8 (26.9)
37.5 (18)

Discourse measures (>200 words)

No. of words

No. of correct information units

% Correct information units

Boston Naming Test

Week 26—Secondary outcomes

75.7 (25.3)

Western Aphasia Battery-Revised AQ

Week 26—Primary outcome

42 (60)

Discourse measures (>200 words; n, %)

Boston Naming Test

31.3 (18.8)

52.9 (29.5)

% Maximal potential recovery

Week 12—Secondary outcomes

70.02 (28.7)

Western Aphasia Battery-Revised
Aphasia Quotient

Week 12—Primary outcome

UC
(n ¼ 70)

Table 5. Outcomes at 12 and 26 weeks post stroke

34.6 (20)

60.5 (27.2)

265 (295)

375 (355)

86 (58)

54.7 (34.6)

71.7 (28.9)

5.6 (3.88)

3.3 (0.87)

55 (28)

212 (246)

316 (307)

80 (54)

30.3 (20.8)

50.5 (32.4)

67.2 (29.9)

High intensity
(n ¼ 147)

0.59 (0.54, 1, 73)

p ¼ 0.30b

0.6 (86.8–88.1)
2.2 (10.6–6.2)
2.9 (8.9–3.1)

p ¼ 0.60b
p ¼ 0.13b

4 (102.8–110.2)

OR ¼ 0.9 (0.4–1.8)

p ¼ 0.99b

p ¼ 0.94a

p ¼ 0.88b

6.9 (15.6–1.7)

1.3 (0.51–0.03)

p ¼ 0.03b

p ¼ 0.12b

3.1 (11.1–4.9)

p ¼ 0.44b

4.0 (11.9–4.0)

42 (30.9–114.4)

p ¼ 0.25b

p ¼ 0.33b

51 (38.9–140.6)

OR ¼ 0.7 (0.4–1.3)

p ¼ 0.26b

p ¼ 0.32a

1.1 (7.0–4.9)

(11.2–6.3)

p ¼ 0.58b

p ¼ 0.73b

2.8 (11.2–5.5)

Mean difference (95% CI)

p ¼ 0.51b

p value

Unadjusted analysis

p ¼ 0.31

p ¼ 0.87

–

–

–

p ¼ 0.09

–

p ¼ 0.31

p ¼ 0.24

p ¼ 0.38

–

–

–

p ¼ 0.31

p ¼ 0.59

–

p value

(11.0–4.1)

(continued)

2.0 (5.9–1.9)

0.64 (8.5–7.2)

–

–

–

6.1 (13.2–1.0)

–

0.57 (0.53, 1.67)

012 (0.33, 0.08)

–

–

–

0.48 (3.3–4.2)

1.9 (8.7–5.0)

–

Mean difference (95% CI)

Adjusted analysis
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UC:: usual care.
a
Chi-square test.
b
t test.
c
Analysis conducted on >200 words.
Data are n (%) or mean (SD). Adjusted analysis accounts for baseline Western Aphasia Battery-Revised Aphasia Quotient, National Institutes of Health Stroke Scale scores as fixed factors and randomizing
sites as a random factor.

0.51 (1.57–0.56)
0.57 (1.70–0.56)
4.76 (3.8)
Aphasia Depression Rating Scale

4.2 (3.3)

p ¼ 0.32b

p ¼ 0.35

0.12 (0.33–0.08)
p ¼ 0.34
0.14 (0.38–0.10)
3.65 (0.76)

3.5 (0.82)

p ¼ 0.23b

p value
Mean difference (95% CI)
p value

Stroke and Aphasia Quality of Life Scale-39

Table 5. Continued

UC
(n ¼ 70)

High intensity
(n ¼ 147)

Unadjusted analysis

Mean difference (95% CI)
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Adjusted analysis
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The contribution of spontaneous recovery to outcome remains elusive. Inclusion of a no treatment
arm was not considered ethical in this pragmatic trial,
given that patients in Australia and New Zealand
expect to receive aphasia therapy in the acute phase
of stroke care. It is likely that the early, rapid recovery
in the ﬁrst six months after stroke seen in this trial is
due to a combination of spontaneous recovery and a
treatment eﬀect. We set about to determine if additional therapy to standard care enhanced spontaneous
recovery rather than attempting to discern the individual value of each component. In the few studies
where there has been an attempt to measure eﬀects of
spontaneous recovery, varied study designs, small participant numbers, diﬀerent measurement time points, or
diﬀerent outcome measures have been used, making
the drawing of conclusions problematic. In a metaanalysis40 of 5928 individual patient data, there are
23 cases5 of documented spontaneous recovery as
part of usual care, that have comparable outcome
measures (completed in English) collected within
14 days (baseline) and 26 weeks post stroke. The
amount of spontaneous language and communication
recovery of this historical control cohort is presented in
the Supplement (Supplemental Figure S4) and indicates a medium eﬀect size well below that seen in the
VERSE trial.
Our results challenge the previously held neurorecovery theoretical perception that ‘more intensive
therapy is better’ when commenced in the ﬁrst two
weeks of stroke onset. The UC therapy regimen of a
mean 9.5 h (SD 7) h, comprising 25- to 45-min sessions
provided three times per week within 38 days (10 days
to randomization and 28 days of intervention) post
stroke may be a suﬃcient therapy regimen to support
recovery in the ﬁrst six months post stroke. However,
deﬁnitive thresholds regarding timing, intensity and
type of therapy are diﬃcult to describe without stronger
data on natural recovery in the acute phase. Similarly,
while this study provided a higher, more intense dose of
aphasia therapy than is common in early usual care
without signiﬁcant beneﬁt, it remains unclear whether
a much higher dose, for example, 100 h over 12 weeks,
would be more eﬃcacious.
This study adds strong additional evidence to the
RATS-33 trial ﬁndings from an internationally diverse,
English speaking population. RATS-33 showed no signiﬁcant diﬀerence between communication recovery at
4, 12 or 26 weeks post stroke after intensive aphasia
therapy in the ﬁrst six weeks of recovery when compared with a delayed intervention control group. The
VERSE results demonstrate no beneﬁt of intensive
aphasia therapy compared to therapy at a lesser intensity in the ﬁrst six weeks of language and communication recovery at 12 and 26 weeks. Together, these
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Figure 2. WAB-R (AQ) Baseline, 12-, and 26-week outcomes with 95% confidence intervals.

trials3–6 provide compelling evidence to challenge the
‘intensive’ mindset in early stroke language and communication recovery.
The question of ‘what is enough?’ therapy is paramount here. Some may propose that the total intervention regimen in this and other trials1,3,4,5,18,40 was
insuﬃcient (below the theoretical threshold of at least
98 h in total19) to demonstrate a beneﬁt of treatment
intensity in this recovery period. We suggest that the
intensity and total hours of intervention in the UC participants presented here demonstrate clinically meaningful change that can be attributed to a combination
of therapy eﬀect and spontaneous recovery.

Directions for future early aphasia
therapy research
There is a risk that a ‘non-aphasia expert’ may misinterpret the results from this study to indicate that early
aphasia therapy or intensive aphasia therapy does not
lead to meaningful beneﬁts post stroke. This study
addresses the speciﬁc issue of ‘more intensive therapy’
in the early recovery period; it did not evaluate chronic
recovery or the eﬀect of ‘treatment’ versus ‘no treatment’. There are several important research areas that
must be addressed in order to deliver improved recovery for people with aphasia. Aphasia research needs
Level 1 evidence to address: (i) the dose response in
early and chronic aphasia recovery; (ii) the optimal
type of therapy to provide to whom and at what time
post stroke; and (iii) what other factors contribute to

early aphasia recovery (e.g. the role of stroke unit care
in clinical improvement). The ability to monitor other
therapies available (i.e. physiotherapy, occupational
therapy) and social interactions was outside the funding
scope of this trial. Within the RCT design, we expect
that the input of other health professionals is similar
across groups. The potential for physical training provided by other therapists, which may oﬀer additional
language practice, to interact with or support language
recovery is currently unexplored, and may be an area
for future study.
Our results do not support increasing aphasia therapy intensity in the ﬁrst 38 days post stroke above what
is reported as UC in this trial, nor support the modiﬁcation of existing services related to type and amount of
aphasia therapy provided in current practice in
Australia and New Zealand for post stroke early aphasia recovery.
In aphasia research fruitful next important areas of
enquiry should include: (i) strong Phase I studies determining the eﬀect of a dose range of identiﬁed active
ingredients; and (ii) Phase II studies establishing feasibility of dose speciﬁc treatment regimens in early aphasia recovery.
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